GlobalData has released its new PharmaPoint Drug Evaluation report, Neratinib (HER2-Positive Breast Cancer) Forecast and Market Analysis to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.
Puma Biotechnologys neratinib is an orally-administered TKI that binds irreversibly, targeting HER1, HER2, and HER4. Neratinib inhibits HER2 at a different site than the currently marketed HER2-targeted therapies, which Puma believes will make it effective in patients who have developed resistance to these other treatments.
- Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Neratinib including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Neratinib for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Neratinib performance
- Obtain sales forecast for Neratinib from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)